Drug Discovery Featured Articles & Applications
-
The 2 Factors Driving A Surge In Aptamer Use In Drug Discovery
5/25/2023
Aptamers offer advantages over antibodies, including lower immunogenicity and toxicity, better tissue penetration, lower production costs, and a very long shelf life. Why, then, have we not seen more of these come to market? Two hurdles have stood in the way until recently.
-
FDA Adopts ICH Guidance On Assessing Nonclinical Biodistribution Of Gene Therapy Viral Vectors
5/23/2023
An important step in the gene therapy development process is assembling biodistribution data in suitable animals in relation to the intended clinical population. Developing an accurate biodistribution profile is influenced by factors such as the route of administration, dose level(s), dosing regimen, and the animal immune response to the gene therapy product. The FDA adopted this ICH guidance in May 2023, and the EMA plans to adopt it in September 2023.
-
Optimizing Digitalization To Accelerate Your R&D
5/19/2023
Drug/therapy development has made significant leaps in innovation in recent years, but common issues that hinder progress still exist. Are you harnessing and optimizing your data for speedier drug development and quicker launch timescales? This article shares important recommendations.
-
Leveraging AI In Drug Discovery To Treat MS & Other Autoimmune Diseases
5/17/2023
The advancement of artificial intelligence and machine learning algorithms means we can use large pools of genetic data to identify potential risk factors and disease-causing genes for multiple sclerosis and other autoimmune diseases. This author shares a three-pronged approach to analyzing data for AI algorithms, pitfalls to avoid, and AI for silico modeling.
-
Key Considerations For Developing Next-Generation Antibody-Drug Conjugates
5/11/2023
Fourteen antibody-drug conjugates (ADCs) have been approved globally for cancer indications so far. This article shares considerations for complementing target with antibody subtype, optimizing format for half-life functionality, and delivering payloads with diverse MOA.
-
India’s CROs & CDMOs Come Of Age In The Global Marketplace
5/4/2023
Most of the top 10 pharmaceutical companies and many large biotech companies today get a portion of their preclinical/clinical research, drug development, and/or manufacturing done in India. While a low price is the initial attraction, there are additional factors that can be more meaningful.
-
5 Characteristics Of The Automated Microbiology Lab Of The Future
4/24/2023
The modern microbiology laboratory is starting to look very different from the laboratory of 10 years ago, and it will continue to evolve in the next few years. There are a number of innovations being implemented now or are in progress that can signal the path that many microbiology laboratories will follow.
-
Risk-Based Strategies For Revalidating Bio/Pharma Equipment & Systems
4/20/2023
While equipment and systems validation is a regulatory requirement, it would take thousands of annual tests to retest all equipment and systems. BioPhorum shares risk-based approaches to new product introduction, controlled temperature chambers, sterilization processes, and more.
-
Congressional Changes For Orphan Drug Approvals?
4/18/2023
Lawmakers are stepping in to increase the number of rare disease and orphan drug experts who sit on advisory committees. As it stands now, advisory committees can include experts who simply have a broad understanding of the overall disease state.
-
Organ-On-Chip Devices Show Promise In Drug Discovery
4/10/2023
There is growing interest in the potential uses for organ-on-chip devices as a novel tool for drug discovery. These devices offer a unique platform that mimics the physiology and function of human organs, providing a more accurate representation of human biology than traditional cell culture systems.